Literature DB >> 18557699

Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.

Emad Bennour1, Christophe Ferrand, Jean-Paul Rémy-Martin, Jean-Marie Certoux, Sebastian Gorke, Waseem Qasim, H Bobby Gaspar, Thomas Baumert, Anne Duperrier, Marina Deschamps, Boris Fehse, Pierre Tiberghien, Eric Robinet.   

Abstract

Donor T cell alloreactivity can be efficiently controlled by retrovirus-mediated ex vivo transfer of a "suicide" gene encoding the wild-type herpes simplex virus thymidine kinase (wtHSV-tk) gene, allowing gene-modified cells (GMCs) to be sensitive to ganciclovir (GCV). A limitation to this approach was related to the presence of an inactive form of the wtHSV-tk gene, resulting from alternative splicing. A corrected HSV-tk (cHSV-tk) gene was developed in order to circumvent this problem and was fused to a truncated splice variant of the human CD34 molecule (tCD34) suitable for the selection of retrovirally transduced GMCs. We demonstrate now that, despite this correction, CD34-positive, but GCV-resistant, HUT and primary GMCs can still be generated after transduction with a retroviral vector encoding a tCD34/cHSV-tk fusion protein (FuProtein). Deletions in the HSV-tk part of the transgene account in part for this resistance. However, an additional mechanism involving proteolytic-dependent "breakage" of the FuProtein has been observed: the CD34 part of the FuProtein can be detected by Western blot, separated from its HSV-tk part. Although the HSV-tk protein alone is not detectable in GCV-resistant tCD34/cHSV-tk-transduced HUT cells, it can be detected in 293T cells transduced with another tCD34/HSVTK fusion vector, demonstrating that a posttranslational effect leads to the breakage of the FuProtein. This is to our knowledge the first example of a loss of function of a FuProtein, of which one part is still expressed while the other one, suffering a selection pressure, is no longer detectable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18557699     DOI: 10.1089/hum.2007.060

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

1.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 2.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

3.  [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility.

Authors:  Linda G Eissenberg; Michael P Rettig; Julie K Ritchey; Julie L Prior; Sally W Schwarz; Jennifer Frye; Brian S White; Robert S Fulton; Armin Ghobadi; Matthew L Cooper; Daniel R Couriel; Muhammad Esa Seegulam; David Piwnica-Worms; Farrokh Dehdashti; Kenneth Cornetta; John F DiPersio
Journal:  Mol Ther       Date:  2015-03-25       Impact factor: 11.454

4.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.